Back to "They showed different results among the ..."
Claim
Strong Support
descriptive
Analysis v3

Different GLP-1 receptor agonist drugs have different effects on cardiovascular outcomes; liraglutide and semaglutide are linked to cardiovascular benefit, while lixisenatide and exenatide are not.

33
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Some GLP-1 drugs stay active in the body longer and reach deeper into blood vessel walls, where they calm inflammation and improve blood flow. Others leave the body too quickly to affect blood vessels the same way, even if they lower blood sugar equally.

Most probable mechanism

In Simple Terms

Some GLP-1 drugs stay in the body longer and reach deeper into blood vessel tissues, which allows them to directly calm inflammation and improve how blood vessels work, while others don't reach far enough or leave too quickly to have the same effect.

Causal chain
1

Liraglutide and semaglutide bind to the GLP-1 receptor with higher affinity and slower dissociation kinetics, prolonging receptor activation in vascular endothelial and smooth muscle cells

Indirect evidence only
which leads to
2

Prolonged receptor activation enhances nitric oxide production and suppresses nuclear factor kappa B signaling in vascular tissues, reducing endothelial inflammation and oxidative stress

Indirect evidence only
which leads to
3

Lixisenatide and exenatide exhibit rapid clearance and shorter receptor residence time, limiting sustained signaling in vascular tissues despite equivalent glycemic control

Indirect evidence only
which leads to
4

Reduced vascular signaling duration fails to suppress chronic low-grade inflammation and arterial stiffening, leaving cardiovascular risk unchanged

Indirect evidence only

Evidence from Studies

Supporting (1)

33

Community contributions welcome

33

Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio

Systematic Review With Meta-Analysis
Human
2018 Jul

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio

Score: 33
DOI: 10.1177/1060028018757407

Similar Assertions

In adults with heart failure, semaglutide and liraglutide lower the risk of death from cardiovascular causes, while tirzepatide and exenatide do not lower this risk.

52
0
87%

Liraglutide and exenatide, drugs that activate GLP-1 receptors, lower the frequency of heart attacks, strokes, and hospitalizations for heart failure by acting directly on the heart and metabolism, regardless of whether they cause weight loss.

38
52
82%

Some diabetes drugs like liraglutide, semaglutide, and dulaglutide may help protect the heart and lower the chance of serious heart problems in people with type 2 diabetes who already have heart disease — and this benefit might not just be because they lower blood sugar.

1
0
81%

Medicines like liraglutide, semaglutide, and tirzepatide can help people with extra weight lose pounds and improve their blood sugar, liver health, cholesterol, and blood pressure.

1
0
80%

If someone has had weight-loss surgery but isn’t losing enough weight—or gains it back—taking semaglutide seems to help them lose more weight than if they took liraglutide, and they’re over twice as likely to lose 10% or more of their body weight.

39
0
76%